- Revenue: C$88.2M ($65.7M), +37% YoY
- Net Income: C$31.2M ($23.2M) vs -C$17.1M loss YoY
- Adjusted EBITDA: C$23.1M ($17.2M), +316% YoY
CEO Miguel Martin: "This quarter was record-breaking for Aurora, driven by all-time highs in global medical net revenue, net income, adjusted EBITDA, and free cash flow. These achievements, along with our strong cash position and debt-free cannabis business, underscore Aurora's leadership in the global cannabis industry."
🌱Revenue & Growth
- Medical Cannabis: C$68.1M ($50.7M), +51% YoY
- Consumer Cannabis: C$9.9M ($7.4M), -15% YoY
- Plant Propagation: C$8.9M ($6.6M), +22% YoY
- International Medical: C$40.9M ($30.5M), +112% YoY, 60% of medical revenue
💰Profits & Financials
- Adjusted Gross Margin: 65% vs 53% YoY
- Medical Cannabis Margin: 74% vs 63% YoY
- Cash Position: C$180M ($134.1M), debt-free cannabis business
- Free Cash Flow: C$27.4M ($20.4M), positive for first time
📌Business Highlights
- Generated first positive free cash flow
- Strong growth in Australia, Germany, Poland, and UK markets
- Successfully increased production efficiency by sourcing European supply from Canada
🔮Future Outlook
- Expects continued revenue growth in cannabis business
- Projects seasonally higher plant propagation revenues
- Forecasts modestly positive free cash flow
- Anticipates margins to remain strong with continued positive adjusted EBITDA